Show simple item record

dc.contributor.authorKaufman, H.L.
dc.contributor.authorAtkins, M.B.
dc.contributor.authorSubedi, P.
dc.date.accessioned2019-09-13T17:02:31Z
dc.date.available2019-09-13T17:02:31Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065867563&doi=10.1186%2fs40425-019-0594-0&partnerID=40&md5=58f5d54bb03295285442e0327611a7f9
dc.identifier.urihttp://hdl.handle.net/10713/10795
dc.description.abstractThe rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies, multiple stakeholders have been considering the question of "What makes I-O transformative?" Evaluating the distinct features and attributes of these therapies, and better characterizing how patients experience them, will inform such assessments. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of their value and seeks to address evidence gaps in existing value frameworks given the unique properties of patient outcomes with I-O therapy. The paper concludes with a "data needs catalogue" (DNC) predicated on the belief that multiple key, unique elements that are necessary to fully characterize the value of I-O therapies are not routinely or robustly measured in current clinical practice or reimbursement databases and are infrequently captured in existing research studies. A better characterization of the benefit of I-O treatment will allow a more thorough assessment of its benefits and provide a template for the design and prioritization of future clinical trials and a roadmap for healthcare insurers to optimize coverage for patients with cancers eligible for I-O therapy. Copyright 2019 The Author(s).en_US
dc.description.sponsorshipDevelopment of this paper was supported by Pfizer Oncology and Merck KGaA.en_US
dc.description.urihttps://doi.org/10.1186/s40425-019-0594-0en_US
dc.language.isoen-USen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.ispartofJournal for ImmunoTherapy of Cancer
dc.subjectImmuno-oncologyen_US
dc.subjectImmunotherapyen_US
dc.subjectPatient experienceen_US
dc.subjectPatient reported outcomes (PROs)en_US
dc.subjectValueen_US
dc.titleThe promise of Immuno-oncology: Implications for defining the value of cancer treatmenten_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s40425-019-0594-0
dc.identifier.pmid31101066


This item appears in the following Collection(s)

Show simple item record